Company Filing History:
Years Active: 2015-2016
Title: Gabor Szeleczky: Innovator in CXCR3 Receptor Antagonists
Introduction
Gabor Szeleczky is a notable inventor based in Budapest, Hungary. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target the CXCR3 receptor. With a total of 2 patents, his work is pivotal in addressing diseases linked to abnormal chemokine activation.
Latest Patents
Gabor Szeleczky's latest patents include innovative compounds that serve as CXCR3 receptor antagonists. The first patent, titled "Substituted B-amino acid derivatives as CXCR3 receptor antagonists," focuses on compounds that are useful for the preventive and therapeutic treatment of diseases caused by abnormal activation of CXCR3 chemokines. This invention also details a process for preparing these compounds, along with pharmaceutical compositions and novel intermediates used in their preparation. The second patent, "Cycloalkane carboxylic acid derivatives as CXCR3 receptor antagonists," similarly addresses the therapeutic potential of compounds that inhibit CXCR3 receptor activity, providing a comprehensive approach to treating related diseases.
Career Highlights
Gabor Szeleczky is currently associated with Sanofi, a leading global healthcare company. His role involves extensive research and development in the pharmaceutical sector, where he applies his expertise to create innovative solutions for complex health issues.
Collaborations
Throughout his career, Gabor has collaborated with talented professionals, including Imre Bata and Veronika Bartane Bodor. These partnerships have enhanced his research efforts and contributed to the successful development of his patented inventions.
Conclusion
Gabor Szeleczky stands out as an influential inventor in the realm of pharmaceutical innovations. His work on CXCR3 receptor antagonists showcases his commitment to advancing medical science and improving therapeutic options for patients.